Q2 2021 Results - Reimagining Medicine
Financial review
Conclusion
Appendix
Participants
Company overview
Pharmaceuticals
Oncology
Financial performance
Innovation: Pipeline overview
References
Innovation: Clinical trials
Regulatory
2021 key pipeline milestones¹
H1 2021
EntrestoⓇ
HFPEF (US)
H2 2021
CosentyxⓇ
Pediatric psoriasis (US ✓ CN/JP)
✓ Achieved
Readout not supportive
decisions
and opinions
KesimptaⓇ
Relapsing MS (EU/JP)
Major
Leqvio®
Hyperlipidemia (US)²
Asciminib (ABL001)
CML 3L (JP)
expected
JakaviⓇ
submissions
TabrectaⓇ
BeovuⓇ
Acute and chronic GVHD (EU/JP) ✓
NSCLC (EU)
DME (US/EU)
BeovuⓇ
H2-2021
Asciminib (ABL001)
CML 3L (US/EU)
CosentyxⓇ
JIA (US/EU)
Major
Iptacopan (LNP023)
Ph2 - IgAN
expected
trial
readouts*
Iptacopan (LNP023) Ph2 - C3G
EntrestoⓇ
Ph3 Post-AMI
Canakinumab
-
Ph3 NSCLC 2L
(ACZ885)
177Lu-PSMA-617
CosentyxⓇ
Ph3 - mCRPC
Ph3 - JIA
H2 20213
ECF843
4
6
Ligelizumab (QGE031)
KisqaliⓇ
Remibrutinib (LOU064)
CosentyxⓇ
Ph3 - HS
Alpelisib (BYL719)
KymriahⓇ
177 Lu-PSMA-617
Tislelizumab (VDT482)
Tislelizumab (VDT482)
Canakinumab (ACZ885)
DME (JP)
PROS (US)
r/r Follicular lymphoma (US/EU/JP)
mCRPC (US/EU)
2L esophageal cancer (US)
NSCLC (US)
Ph3 - NSCLC 1L
Ph2 - Dry eye
Ph3 - CSU5
Ph3 aBC (MONALEESA-2 OS)
-
Ph2 - CSU
8
Sabatolimab (MBG453) Ph2 - MDS7
KymriahⓇ
-
Ph3 aNHL 2L
2. Resubmitted to FDA 3. Ph2 interim data presented 4. Numerical trends
*Achieved on-time readout of data, irrespective of trial outcome. 1. 2021 Key milestone table may evolve based on read-out outcomes as well as BD&L activities.
consistently favored EntrestoⓇ vs. active comparator but did not meet primary composite endpoint. The safety profile of EntrestoⓇ was confirmed. No submission planned.
7. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial.
5. Q4/2021-Q1/2022 potential COVID impact. 6. Negative readout
8. Program discontinued in broad population of moderate to severe DED.
46 Investor Relations | Q2 2021 Results
U NOVARTIS | Reimagining MedicineView entire presentation